Pneumonia & Pandemic Preparedness | Pandemic PACT Tracker

Key facts

Disease
COVID-19
Start & end year
2021
2021
Known Financial Commitments (USD)
$1,760,539
Funder
Gates Foundation
Principal Investigator
N/A
Research Location
United States of America
Lead Research Institution
Calibr-Skaggs Institute for Innovative Medicines
Research Priority Alignment
N/A

Research Category
Therapeutics research, development and implementation
Research Subcategory
N/A
Special Interest Tags
N/A
Study Type
Unspecified
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified

Abstract

to deliver a drug candidate to treat coronavirus diseases

Publicationslinked via Europe PMC

Last Updated:32 minutes ago

View all publications at Europe PMC

Correction to "Discovery of CMX990: A Potent SARS-CoV-2 3CL Protease Inhibitor Bearing a Novel Warhead".

Authors
Elshan NGRD, Wolff KC, Riva L, Woods AK, Grabovyi G, Wilson K, Pedroarena J, Ghorai S, Nazarian A, Weiss F, Liu Y, Mazumdar W, Song L, Okwor N, Malvin J, Liu D, Bakowski MA, Beutler N, Kirkpatrick MG, Gebara-Lamb A, Huang E, Nguyen-Tran VTB, Chi V, Li S, Rogers TF, McNamara CW, Gupta AK, Rahimi A, Chen JJ, Joseph SB, Schultz PG, Chatterjee AK.
Publish Year
2024
Journal
Journal of medicinal chemistry
DOI
10.1021/acs.jmedchem.4c01269

View at Europe PMC

Discovery of CMX990: A Potent SARS-CoV-2 3CL Protease Inhibitor Bearing a Novel Warhead.

Authors
Dayan Elshan NGR, Wolff KC, Riva L, Woods AK, Grabovyi G, Wilson K, Pedroarena J, Ghorai S, Nazarian A, Weiss F, Liu Y, Mazumdar W, Song L, Okwor N, Malvin J, Bakowski MA, Beutler N, Kirkpatrick MG, Gebara-Lamb A, Huang E, Nguyen-Tran VTB, Chi V, Li S, Rogers TF, McNamara CW, Gupta AK, Rahimi A, Chen JJ, Joseph SB, Schultz PG, Chatterjee AK.
Publish Year
2024
Journal
Journal of medicinal chemistry
DOI
10.1021/acs.jmedchem.3c01938

View at Europe PMC